Newsletter
| Promoter: | ShiznitStocks | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| PMCB | $2000 | UNKNOWN |
| Max Profit: 9.60 % | Gain at close: 0.00 % | |
| *We think that this promoter is a part of a group of promoters. | ||
 Morning folks, PMCB gapped up nicely this morning hitting $0.1175 - a 19% from our alert yesterday. If you are in this, don't forget to take gains along the way. If you are on the sidelines, keep watching this one for dips and opportunities to get in. Congrats again. Shiznit ----------------------------------------------------------------------------------------
Hello fellow investors / traders, We had a solid 30%+ winner today, and i believe there is plenty more gains ahead.
Today I want you to check out PharmaCyte Biotech Inc (PMCB) A few days ago PCMB provided investors an update on their Cancer and Diabetes programs check it out at http://finance.yahoo.com/news/pharmacyte-biotech-provides-corporate-developments-123000857.html
PMCB is a highly liquid trader that has pulled back significantly over the past few months.
Now it rests at strong multi-month support at $0.10.
If this support continues to hold, there is only one way for PMCB to go - and that's higher Buying at support levels has proven to be one of the most simple and profitable trading strategies. That's because the risk v reward is so much more favorable.
Think about it. If you buy a stock at or near long term support levels, you set your stop just below this level. Your risk is small and well defined. And given the 100 and 200 day moving average in PMCB is $0.16 and $0.19 respectively, and recent highs were around $0.26, there is a lot of potential upside. In other words, there could be 50-75% short term upside, while only 10% downside if you place your stops just below support. Of course we think the long term potential is so much greater, but as investors and traders we must focus on the short and long term.
PMCB is a clinical stage biotechnology company developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology Cell-in-a-Box®. PMCB's Cell-in-a-Box® is a way to enclose living cells in protective "cocoons" about the size of the head of a pin - These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. Reasons we're excited about this stock:
This is why we're excited to bring you a company in phase 2b of clinical trials for treating the terrible disease. So while their current clinical trials are centered around the ability to treat pancreatic cancer, there is potential for this technology to treat several forms of cancer. Biotechs can yield some of the largest returns out of any other industry in the microcap space, so when we find one with a story like this, we get pretty excited. Make sure you're ready to book your profits with PMCB! - See more at: http://whisperfromwallstreet.com/clinical-stage-biotech-gets-fast-tracked-pmcb/#sthash.okL1L2zW.dpuf
PMCB is a clinical stage biotechnology company developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology Cell-in-a-Box®. PMCB's Cell-in-a-Box® is a way to enclose living cells in protective "cocoons" about the size of the head of a pin - These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. Reasons we're excited about PMCB 1. This technology shows great promise. As a matter of fact, in the first round of testing patients received two courses of ifosfamide at one-third the regular dose plus a urological protectant after transplantation of 300 capsules. Median survival after diagnosis rose to 40 weeks, compared with historical control of 28 weeks with gemcitabine, and 1-year survival increased to 36%, compared with 18% for gemcitabine. 2. The European Medicines Agency (The European version of the FDA) has fast-tracked this treatment in order to cut the time it takes to get to market. That is obviously a great thing for patients and investors. 3. PMCB's cell- in-a-box technology was named a Near Term Approach in the The Journal of the National Cancer Institute. The JNCI was established in 1940 and is internationally acclaimed as the source for the most up-to-date news and information from the rapidly changing fields of cancer research and treatment. Coverage in the Journal of the National Cancer Institute brings the kind of credibility that investors like to see when making long term bets on microcap companies. We are excited to bring you a company in phase 2b of clinical trials for treating the terrible disease. So while their current clinical trials are centered around the ability to treat pancreatic cancer, there is potential for this technology to treat several forms of cancer.
Recent News
I am really excited about the short and longer term trade opportunity in PMCB at these levels.
Please do your research now and make sure you're ready to bank at the opening bell.Disclaimer Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. For full disclaimer click here. ShiznitStocks.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead ShiznitStocks.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. ShiznitStocks.com does not offer such advice or analysis, and ShiznitStocks.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, ShiznitStocks.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, ShiznitStocks.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. ShiznitStocks.com is not responsible for any claims made by the companies advertised herein. ShiznitStocks.com may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in ShiznitStocks.com statements and opinions and such statements and opinions cannot be considered independent. ShiznitStocks.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, ShiznitStocks.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. ShiznitStocks.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the companies profile. ShiznitStocks.com has been compensated two thousand dollars via electronic transfer from a non-affiliated third party for the profile of PMCB. ShiznitStocks.com may on occasion accept compensation in restricted or free-trading shares for it's marketing services of the company being profiled, and the third party that might have compensated ShiznitStocks.com may hold free-trading shares of the company being profiled and could very well be selling shares of the companies stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. If ShiznitStocks.com ever accepts compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services. |